BioSpace News Archive

Vivos Therapeutics, Inc. announced the results of a recent clinical observational study on the application of Vivos’ recently acquired Preventive Oral Device® in the treatment and prevention of migraine headaches.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2023.

Indaptus Therapeutics, Inc. announces the Company’s Chief Scientific Officer, Michael Newman, Ph.D., has been named chair for two of the three days of the 4th STING & TLR-Targeting Therapies Summit to be held in Boston on May 9-11, where he will also be a featured speaker.

Elicio Therapeutics announced that interim data from the Phase 1 study of its lead asset, ELI-002, will be presented in a poster discussion presentation at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, a hybrid event taking place online and at McCormick Place in Chicago from June 2-6, 2023.

Mineralys Therapeutics, Inc. announced it will report its financial results from the first quarter ended March 31, 2023, after the financial markets close on Monday, May 15, 2023.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors.

Akari Therapeutics, Plc today announced financial results and highlights for the full year ended December 31, 2022, as well as recent company updates.

Immutep Limited announces it has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha in combination with BAVENCIO® in up to 30 patients with metastatic urothelial carcinoma.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases announced the release of its inaugural Environmental, Social, and Governance Report.

SIRPant Immunotherapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application for the Company’s lead product candidate, SIRPant-M™, an autologous SIRPαlow activated macrophage therapy for the treatment of aggressive tumors.